SARS-CoV-2 susceptibility and COVID-19 illness course and outcome in people with pre-existing neurodegenerative disorders: systematic review with frequentist and Bayesian meta-analyses

Muhannad Smadi; Melina Kaburis; Youval Schnapper; Gabriel Reina; Patricio Molero; Marc L. Molendijk

doi:10.1192/bjp.2023.43

SARS-CoV-2 susceptibility and COVID-19 illness course and outcome in people with pre-existing neurodegenerative disorders: systematic review with frequentist and Bayesian meta-analyses

Published online by Cambridge University Press: 15 May 2023

Patricio Molero and

Muhannad Smadi: Affiliation:
Institute of Psychology, Department of Clinical Psychology, Leiden University, Leiden, The Netherlands
Melina Kaburis: Affiliation:
Institute of Psychology, Department of Clinical Psychology, Leiden University, Leiden, The Netherlands
Youval Schnapper: Affiliation:
Institute of Psychology, Department of Clinical Psychology, Leiden University, Leiden, The Netherlands
Gabriel Reina: Affiliation:
Navarra Institute for Health Research (IdiSNA), Pamplona, Spain; and Clínica Universidad de Navarra, Department of Microbiology, Pamplona, Spain
Patricio Molero: Affiliation:
Navarra Institute for Health Research (IdiSNA), Pamplona, Spain; and Clínica Universidad de Navarra, Department of Psychiatry and Medical Psychology, Pamplona, Spain
Marc L. Molendijk*: Affiliation:
Institute of Psychology, Department of Clinical Psychology, Leiden University, Leiden, The Netherlands; and Leiden Institute for Brain and Cognition, Leiden University Medical Centre, Leiden, The Netherlands
*: Correspondence: Marc L. Molendijk. Email: m.l.molendijk@fsw.leidenuniv.nl

Article contents

Abstract
Background
Aims
Method
Results
Conclusions
Method
Results
Discussion
Data availability
Author contributions
Funding
Declaration of interest
References

Rights & Permissions

Abstract

Background

People with neurodegenerative disease and mild cognitive impairment (MCI) may have an elevated risk of acquiring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and may be disproportionally affected by coronavirus disease 2019 (COVID-19) once infected.

Aims

To review all eligible studies and quantify the strength of associations between various pre-existing neurodegenerative disorders and both SARS-CoV-2 susceptibility and COVID-19 illness course and outcome.

Method

Pre-registered systematic review with frequentist and Bayesian meta-analyses. Systematic searches were executed in PubMed, Web of Science and preprint servers. The final search date was 9 January 2023. Odds ratios (ORs) were used as measures of effect.

Results

In total, 136 primary studies (total sample size n = 97 643 494), reporting on 268 effect-size estimates, met the inclusion criteria. The odds for a positive SARS-CoV-2 test result were increased for people with pre-existing dementia (OR = 1.83, 95% CI 1.16–2.87), Alzheimer's disease (OR = 2.86, 95% CI 1.44–5.66) and Parkinson's disease (OR = 1.65, 95% CI 1.34–2.04). People with pre-existing dementia were more likely to experience a relatively severe COVID-19 course, once infected (OR = 1.43, 95% CI 1.00–2.03). People with pre-existing dementia or Alzheimer's disease were at increased risk for COVID-19-related hospital admission (pooled OR range: 1.60–3.72). Intensive care unit admission rates were relatively low for people with dementia (OR = 0.54, 95% CI 0.40–0.74). All neurodegenerative disorders, including MCI, were at higher risk for COVID-19-related mortality (pooled OR range: 1.56–2.27).

Conclusions

Our findings confirm that, in general, people with neurodegenerative disease and MCI are at a disproportionally high risk of contracting COVID-19 and have a poor outcome once infected.

Keywords

Alzheimer's disease coronavirus disease 2019 dementia mild cognitive impairment Parkinson's disease

Information

Type: Review
Information: The British Journal of Psychiatry , Volume 223 , Issue 2 , August 2023 , pp. 348 - 361

DOI: https://doi.org/10.1192/bjp.2023.43 [Opens in a new window]
Creative Commons: This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright: Copyright © The Author(s), 2023. Published by Cambridge University Press on behalf of the Royal College of Psychiatrists

The novel ‘coronavirus disease 2019’ (COVID-19) is a widespread public health threat that is caused by a highly transmissible respiratory pathogen, ‘severe acute respiratory syndrome (SARS-CoV-2)’.^{Reference John, Ali, Marsh and Reddy1,Reference Liu, Sun, Wang, Zhao, Huang and Li2} Although much has returned to normal in our everyday lives, the virus continues to spread and infect millions and to be lethal to thousands of people on a daily basis, across the globe.^{Reference El-Sadr, Vasan and El-Mohandes3} Early in the pandemic, it became clear that there are individual differences in COVID-19 infection susceptibility and severity.^{Reference Chojnicki, Neumann-Podczaska, Seostianin, Tomczak, Tariq and Chudek4} More than half of all COVID-19 casualties and intensive care unit (ICU) admissions were older adults.⁵

Both age and age-related comorbidities are known to be strong risk factors for the development of dementia.^{Reference Bulut and Kato6–10} The dementias (i.e. Alzheimer's disease; Parkinson's disease with dementia; and mild cognitive impairment (MCI)) are a leading cause of impairment, dependence and mortality, especially among the elderly.^{10,Reference Wu, Zhang, Huang, Dong, Tan and Yu11} People with dementia, including MCI, are more likely to have comorbid conditions that confer a vulnerability for other medical conditions, including COVID-19.^{Reference Chung, Chang, Jeon, Shin, Song and Kim12} In addition, studies have suggested that individuals who have comorbid conditions are more likely to experience severe illness and require hospital admission due to COVID-19 infection.^{Reference Petrilli, Jones, Yang, Rajagopalan, O'Donnell and Chernyak9,Reference Suleyman, Fadel, Malette, Hammond, Abdulla and Entz13} Previous data suggest that a dysregulated immune response in people with dementia can put them at further risk for COVID-19, leading to poor outcome, including death.^{Reference Lutshumba, Nikolajczyk and Bachstetter14–Reference Shi, Chu, Tian, Aerqin, Zhu and Zhu16} Furthermore, people with dementia have been particularly susceptible to the stressors brought on by the pandemic and the social restrictions to help deter the spread of the virus.^{Reference Bianchetti, Rozzini, Bianchetti, Coccia, Guerini and Trabucchi17} In particular, social distancing may worsen stress in people with dementia owing to a disruption in routines developed to compensate for their memory loss.^{Reference John, Ali, Marsh and Reddy1}

Age-related comorbidities, immune dysregulation and exposure to stressors, as well as a reduced ability to comprehend the risks of infection and follow strict protocols to mitigate the spread of the virus, have all been related to infection risk and disease course.^{Reference John, Ali, Marsh and Reddy1,Reference Bianchetti, Rozzini, Bianchetti, Coccia, Guerini and Trabucchi17–Reference Shea, Wan, Chan and DeKosky19} Consequently, people with dementia may be more susceptible to SARS-CoV-2 infection and a relatively poor course and outcome of this disease once infected.^{Reference Butler and Barrientos20} A meta-analysis conducted early in the pandemic found a higher risk of death due to COVID-19 in those with dementia compared with those without dementia.^{Reference Liu, Sun, Wang, Zhao, Huang and Li2} However, the authors reported substantial heterogeneity which remained unexplained, and there was evidence of publication bias. A later meta-analysis showed that the risk for mortality was higher in people with pre-existing dementia.^{Reference Alves, Casemiro, Araujo, Lima, Oliveira and Fernandes21} A limitation of both meta-analyses is the small number of studies synthesised and the likelihood of duplicate data, as both included nationwide data from Italy and Korea multiple times, which may invalidate results.^{Reference Broad22–Reference von Elm, Poglia, Walder and Tramèr25} Therefore, we considered conducting an updated meta-analysis. Another reason for such an update is the rapidly evolving situation and recent influx of publications. In addition, past meta-analyses focused solely on dementia and not its precursor, MCI.

The current meta-analysis aims to quantify all eligible cohort studies reporting on infection risk for COVID-19 and course of disease due to COVID-19 as a function of dementia status. We hypothesise that individuals with pre-existing dementia or MCI are more likely to become infected with SARS-CoV-2 and to experience worse COVID-19 severity and outcome (i.e. COVID-19-related hospital admission, ICU admission or mortality).

Method

The searches and methodology of this systematic review and meta-analysis are reported in accordance with the guidelines set out by Meta-analyses of Observational Studies in Epidemiology (MOOSE)^{Reference Stroup, Berlin, Morton, Olkin, Williamson and Rennie26} and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).^{Reference Moher, Liberati, Tetzlaff and Altman27} A review protocol was drafted and pre-registered with the PROSPERO database (registration number CRD42022299941) and with the Open Science Framework (OSF).

Search and selection strategy

Systematic searches were executed in PubMed and Web of Science. These were supplemented with a non-systematic search in Google Scholar. A grey literature search on the preprint servers PsyArXiv and MedArXiv was also executed. The final search date was 9 January 2023. The search string and terms used per database are presented in the supplementary material available online at https://dx.doi.org/10.1192/bjp.2023.43. Eligibility of article inclusion was assessed independently by four members of the research team masked to each other's assessments, based on (a) title and abstract of potential papers, followed by (b) full-text assessment. A final decision on eligibility was made by four members of the review team (M.S., M.L.M., Y.S. and M.K.) based on the set eligibility criteria.

Eligibility criteria

Articles were included when they (a) reported SARS-CoV-2 infection rates (determined by any of the diagnostic methods, including blood, saliva analysis, polymerase chain reaction (PCR) and antibody testing) and the effect of infection on illness course of COVID-19, including mortality in people with pre-existing dementia (any type, including MCI) compared with controls; and (b) were written in English, Dutch, Spanish, Arabic, Hebrew, German, Italian or French. Articles were excluded if (a) no relevant outcome data could be extracted, (b) no original data were reported (e.g. reviews) or (c) they were case studies. When articles used data that we suspected might be overlapping, we included the article that was most informative for our purposes (see Article selection and overlapping data-sets in the supplementary material).

Exposure and outcome variables

Exposure variables were pre-existing dementias, including the precursor condition MCI, as defined by DSM-IV, DSM-5,^28,29 ICD-10³⁰ or other validated assessment tools, compared with reference groups of people without a dementia. Outcome variables of interest included (a) SARS-CoV-2 infection risk (risk of getting infected with COVID-19), presented as the percentage of SARS-CoV-2 positive tests in the populations under study and (b) the course of COVID-19, further specified as (i) indicators of severity of the disease (e.g. symptomatic versus non-symptomatic, requiring respiratory assistance or not), (ii) hospital admission rates, (iii) ICU admission rates and (iv) COVID-19-related mortality rates.

Data extraction

The following data were extracted from eligible articles: average age (as mean or median in years), gender distribution at follow-up, country in which the study was performed; clinical data (i.e. method of diagnostic assessment, type of disorder), validity of assessment, the covariates that were used in statistical analyses, differences in outcome in covariate adjusted and unadjusted models, whether time-varying covariates were used, the analytical strategy that was used; and raw numbers or effect-size estimates and corresponding 95% confidence intervals (95% CIs) on outcome data. Data extraction was performed independently and masked, by at least two members of the review team (M.S., M.L.M., Y.S. and/or M.K.).

Measures of effect

We extracted ORs and corresponding 95% CIs as measures of effect. Where reported, we extracted data from analyses that controlled for the largest number of potential confounders or that came from (propensity-) matched samples. When results were reported as hazard ratios or risk ratios and raw data were not available, we interpreted these as an OR when the incidence of the reported outcome was <20%. Hazard ratios and risk ratios based on data reporting on an incidence of outcome >20% were transformed.^{Reference Davies, Crombie and Tavakoli31–Reference Zhang and Yu33}

Assessment of methodological quality

The methodological quality of input studies was scored by three members of the review team (M.S., M.L.M. and Y.S.), who were masked to each other's assessment, using the Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies recommended by the US National Institutes of Health.³⁴

Statistical analysis

All analyses were performed in JASP version 0.17.1 for Apple Silicon (JASP Team, University of Amsterdam, Netherlands; https://jasp-stats.org/download). To check the robustness of results, analyses were also performed in IBM SPSS Statistics version 28 for Macintosh and STATA version 17 for Macintosh. Random-effects frequentist meta-analyses were used to pool the data on SARS-CoV-2 infection risk, COVID-19 course, hospital admissions, ICU admissions and mortality rates in relation to the types of pre-existing dementia. Statistical significance was set at P < 0.05. Heterogeneity among studies was quantified using the I ² measure and assessed for statistical significance using the Q ² statistic.^{Reference Sterne, Bradburn and Egger35} Meta-analyses were repeated using a Bayesian approach to verify robustness of results over different analytical approaches. When heterogeneity in outcome was present, subgroup and meta-regression analyses were performed with the aim of identifying study or population characteristics that might explain the heterogeneity. Potential moderators included the percentage of females, average age and methodological quality scores per sample. Subgroup analysis by geographical region was also performed if heterogeneity in outcome was present. Publication bias was assessed by means of Kendall's tau.^{Reference Sterne, Bradburn and Egger35}

Results

Of the 5548 candidate articles that we retrieved, 136 met the eligibility criteria (Fig. 1). Supplementary Tables 1 and 2 list all the articles that were included for full-text assessment as well as reasons for final inclusion and exclusion.

Fig. 1

Flowchart on identification, screening and inclusion of eligible publications. ICU, intensive care unit.

Tables 1 and 2 provide demographic and clinical information on the samples in the studies included, stratified by SARS-CoV-2 susceptibility and COVID-19 course and outcome, respectively. The median age was 70.1 years (range 35–89.5 years), the percentage of females was 53% (range 31–82%) and the median sample size per analysis was 94 624 (range 46–62 250 998). The methodological quality of the majority of input studies was high (Supplementary Tables 16 and 17). Supplementary Box 2 lists studies in which data-sets were (suspected to be) used more than once and the choices that we subsequently made to ensure that data on which we performed our analyses were independent. Supplementary Tables 3(a) and 3(b) provide further information on potential overlap and actions taken per analysis. It should be noted that when nationwide data were available for analysis alongside data gathered more locally, we ran analyses once with the nationwide data included and the local data excluded and once with the local data included and the nationwide data excluded. Therefore, we occasionally reported on fewer data-sets per analysis relative to the numbers provided in the flowchart.

Table 1.

Characteristics of the studies included and samples reporting on SARS-CoV-2 infection risk.

a. Studies are divided by outcome: ‘infection risk’ and ‘course and outcome’. The latter includes only participants with positive COVID-19 infection.

AVG., average (mean); MED., median; AD, Alzheimer's disease; n.a., not applicable; CI, cognitive impairment; Dem, dementia; Mix, mixed dementia; PD, Parkinson's disease.

Table 2.

Characteristics of the studies included and samples reporting on COVID-19 course and outcome.

a. Studies are divided by outcome: ‘infection risk’ and ‘course and outcome’. The latter includes only participants with positive COVID-19 infection.

AVG., average (mean); MED., median; AD, Alzheimer's disease; n.a., not applicable; CI, cognitive impairment; Dem, dementia; DLB, dementia with Lewy bodies; FTD, frontotemporal dementia; MCI, mild cognitive impairment; Mix, mixed dementia; PD, Parkinson's disease; VD, vascular dementia; KSA, Kingdom of Saudi Arabia; N. Ireland, Northern Ireland; 1, infection risk; 2, severity; 3, intensive care unit admission; 4, hospital admission; 5, mortality.

SARS-CoV-2 infection risk

The odds for a SARS-CoV-2 positive test result were increased for people with documented pre-existing dementia (OR = 1.83, 95% CI 1.16–2.87; Table 3). These results were evident in multivariable analyses controlling for potential confounding factors such as age, gender and other comorbidities, but not in crude analyses (Supplementary Table 5). Alzheimer's disease, Parkinson's disease and mixed dementia were all associated with an increase in SARS-CoV-2 susceptibility (Fig. 2). When replacing nationwide data with local data, an increase in SARS-CoV-2 susceptibility remained evident in people with Alzheimer's disease, but not in those with the other disorders (Supplementary Table 4). Between-study heterogeneity in outcome was evident in all analyses (Table 3 and Supplementary Table 5). A small positive association between percentage of females and odds for infection was found in people with dementia (Supplementary Table 7). Methodological quality was not associated with between-study heterogeneity (Supplementary Table 6). The odds for infection risk for all categories of neurodegenerative disorder were not evident in the data gathered in Asia, except for dementia (Supplementary Table 9).

Table 3

Neurodegenerative disorders and SARS-CoV-2 infection risk from multivariable analyses

n.a., not applicable.

a. Estimates come from analyses including nationwide data, at the expense of local data, hence the number of studies (k) is relatively low.

*P < 0.05, **P < 0.01, ***P < 0.001.

COVID-19 course and outcome

People with pre-existing dementia were more likely to experience a severe COVID-19 course, once infected, relative to people in control conditions (OR = 2.66, 95% CI 1.16–6.12; Supplementary Table 5). This was also evident, although with attenuated effect size, in studies utilising multivariable analyses (OR = 1.43, 95% CI 1.00–2.03; Table 4). People with pre-existing dementia were at lower risk for ICU admission (OR = 0.54, 95% CI 0.40–0.74), but at higher risk for COVID-19-related hospital admission (OR = 1.60, 95% CI 1.09–2.35) and mortality (OR = 1.58, 95% CI 1.39–1.79; Fig. 3) in studies utilising multivariable analyses (Table 4). People with Alzheimer's disease were at higher risk for COVID-19-related hospital admission (OR = 3.72, 95% CI 2.35–5.90), but people with MCI, Parkinson's disease or mixed dementia were not. Based on a single study, it was found that people with Alzheimer's disease or Parkinson's disease were at higher risk for COVID-19-related ICU admissions (pooled OR range: 1.55–1.65; Table 4). All patient groups were at higher risk for COVID-19-related mortality (pooled OR range: 1.56–2.27; Table 4). When replacing nationwide data with local data, higher odds for COVID-19-related mortality remained evident for people with dementia or Parkinson's disease (Supplementary Table 4). Between-study heterogeneity in outcome was observed in most analyses (see Table 4 for two exceptions). Average age was positively associated with odds for COVID-19-related hospital admission in people with Parkinson's disease (Supplementary Table 8). In crude analyses, average age was positively associated with odds for mortality in people with dementia or Alzheimer's disease (Supplementary Table 7). The percentage of females was positively associated with odds for mortality in people with Alzheimer's disease in studies utilising crude analyses (Supplementary Table 7) and in people with MCI in studies utilising multivariable analyses (Supplementary Table 8). Methodological quality was not associated with any of the outcomes (Supplementary Tables 7 and 8). The odds of experiencing severe COVID-19, hospital admission, ICU admission and mortality for all categories of neurodegenerative disorders differed by continent (Supplementary Tables 9 and 10).

Table 4

Neurodegenerative disorders and COVID-19 severity, hospital admission, intenrtsive care unit admission and mortality from multivariable analyses

n.a., not applicable.

a. Estimates come from analyses including nationwide data, at the expense of local data, hence the number of studies (k) is relatively low.

*P < 0.05, **P < 0.01, ***P < 0.001.

Fig. 2

Forest plot of pooled effect estimates for SARS-CoV-2 infection risk across all disorders.

Fig. 3

Forest plot of pooled effect estimates for COVID-19 mortality in people with dementia.

Bayesian meta-analysis

Supplementary Tables 11–14 present the odds ratios and 95% confidence intervals based on Bayesian analysis. For ease of comparison, frequentist results are also reported in these tables. Overall, the Bayesian analyses yielded largely similar results to the frequentist approach across all neurodegenerative disorders and the evidence for the alternative hypotheses, in case of significant findings, ranges from moderately strong (Bayes factor between 3 and 10) to extremely strong (Bayes factor >100).

Discussion

This systematic review with meta-analysis, which synthesised 136 primary studies, corroborates that individuals with pre-existing neurodegenerative disorders (i.e. dementia, Alzheimer's disease, Parkinson's disease, MCI or mixed dementia) have an increased susceptibility for SARS-CoV-2 infection and, in general, have higher morbidity and mortality rates for COVID-19. A notable observation is the lower risk for ICU admission in people with dementia. Large sample sizes and convergence of findings using both the frequentist and the Bayesian methods suggest robustness of the findings.

Susceptibility for SARS-CoV-2 infection and neurodegenerative disorders

The odds of infection with SARS-CoV-2 are about 1.5 to 3.0 times higher in individuals with pre-existing neurodegenerative disorders. Age and gender are known risk factors for various chronic diseases.^{Reference Bellou, Tzoulaki, van Smeden, Moons, Evangelou and Belbasis172} In fact, older individuals are more susceptible to SARS-CoV-2^{Reference Wang, Baker, Quan, Shen, Fekete and Gu173} because of age-related changes in the immune system, which deteriorate immune response and efficiency.^{Reference Azarpazhooh, Amiri, Morovatdar, Steinwender, Rezaei Ardani and Yassi18,Reference Nikolich-Zugich, Knox, Rios, Natt, Bhattacharya and Fain174} The living conditions of individuals with a neurodegenerative disorder may be a risk factor, since long-term care facilities (e.g. nursing homes) are predominantly tenanted by the elderly, 48–50.4% of whom have Alzheimer's disease or other dementias.^{10,Reference Harris-Kojetin, Sengupta, Park-Lee, Valverde, Caffrey and Rome175} The combination of age and age-related comorbidities (e.g. neurodegenerative disorders) with proximity and exposure of vulnerable individuals in communal housing, through shared (overcrowded) spaces, may translate to increased susceptibility to COVID-19.^{Reference Bianchetti, Rozzini, Bianchetti, Coccia, Guerini and Trabucchi17} Nevertheless, associations that were controlled for age also yielded significant findings. Additionally, factors such as poor health behaviour (e.g. decreased physical activity) and non-adherence to public health measures may play a significant role in explaining the increased risk for infection with SARS-CoV-2 in individuals with neurodegenerative disorders. This may be attributed to the inability to comprehend the severity of contracting the virus and thus the necessity of complying with the protocols, owing to memory loss and cognitive impairment in individuals with dementia or MCI.^{Reference Liu, Sun, Wang, Zhao, Huang and Li2,Reference Bianchetti, Rozzini, Bianchetti, Coccia, Guerini and Trabucchi17} A further explanation may be an unwillingness to adhere to the measures owing to apathy,^{Reference Liu, Sun, Wang, Zhao, Huang and Li2} which is evident in individuals with dementia.^{Reference Cagnin, Di Lorenzo, Marra, Bonanni, Cupidi and Laganà176} There were no data on whether there was preferential testing among people with dementia that might have led to an increased likelihood of having a diagnosis.

In some instances, we were unable to run subgroup analyses for some of the disorder types by continent (e.g. Asia) owing to the lack of data. Nevertheless, there were some differences in SARS-CoV-2 susceptibility among the geographic continents (i.e. Asia, America, Europe). This might be explained by the financial opportunities of each country to implement safety measures. In addition, owing to better financial resources and advanced medical technology, such as laboratories, (self-) diagnostic kits, and public and private funded testing stations in high-income countries, more cases have been detected in high-income countries compared with low-income countries.^{Reference Bayati177} Similarly, nursing homes, more common in high-income countries, tend to have a larger elderly population than in low-income countries, which may also explain differences among continents.^{Reference Azarpazhooh, Amiri, Morovatdar, Steinwender, Rezaei Ardani and Yassi18}

Severity, course and outcome of SARs-CoV-2 and neurodegenerative disorders

Individuals with most types of pre-existing neurodegenerative disorder are disproportionally affected by COVID-19 once infected. These effects were evident over disease types and outcome, suggesting an approximately twofold increase in risk of more severe illness, and a relatively poor course and outcome, for people with pre-existing dementia, and about a fourfold increase in risk of hospital admission in people with Alzheimer's disease. It has conclusively been shown that age is a risk factor for severe COVID-19.^{Reference Statsenko, Al Zahmi, Habuza, Almansoori, Smetanina and Simiyu178} However, analyses controlled for age yielded similar findings. A possible explanation for the observed findings may be deleterious interactions between COVID-19 and some specific clinical presentations and comorbidities inherent in neurodegenerative disorders. The atypical manifestation of COVID-19 symptoms in the elderly may lead to a delay in detection and diagnosis of the virus, accelerating the risk of developing severe complications and therefore resulting in a higher risk of hospital admission and ICU admission.^{Reference Dadras, SeyedAlinaghi, Karimi, Shamsabadi, Qaderi and Ramezani179,Reference Putri, Hariyanto, Hananto, Christian, Situmeang and Kurniawan180} In addition, dementia is associated with oropharyngeal dysphagia,^{Reference Rajati, Ahmadi, Naghibzadeh and Kazeminia181} a serious comorbidity or complication that independently increases the risk of pneumonia, malnutrition and mortality.^{Reference Banda, Chu, Chen, Kang, Jen and Liu182} Furthermore, Parkinson's disease, dementia and dysphagia are well-known independent and substantial risk factors for pneumonia,^{Reference Torres, Peetermans, Viegi and Blasi183} which is a common cause of death in advanced dementia.^{Reference Mitchell, Teno, Kiely, Shaffer, Jones and Prigerson184} A notable exception that was observed is that people with pre-existing dementia are less likely to be admitted to an ICU because of COVID-19. We are not aware of any studies showing that widespread vaccination altered this association. This finding might best be explained by the triage criteria (e.g. age, frailty and likelihood of benefit) commonly used in disaster situations to maximise the number of survivors.^{Reference Antommaria, Gibb, McGuire, Wolpe, Wynia and Applewhite185,Reference Bledsoe, Jokela, Deep and Snyder Sulmasy186} In countries such as Belgium and the UK, it is advised against admitting to an ICU individuals aged 65 years or older presenting a Clinical Frailty Scale (CFS) score ≥5, who have been diagnosed with COVID-19 or are suspected of having contracted the virus.^{Reference De Smet, Mellaerts, Vandewinckele, Lybeert, Frans and Ombelet90,187} Another significant finding is that individuals with pre-existing neurodegenerative disorders are at higher risk for mortality. This finding is in line with previous studies, demonstrating that in 2020, recorded deaths from Alzheimer's disease and from dementia were respectively 13% and 17% higher than expected, compared with 5 years earlier.^10,188 It should be noted that we conducted separate meta-analyses focused on unadjusted effect estimates and on adjusted effect estimates, and all associations yielded significant findings when adjusted for age and gender.

The results of these meta-analyses raise the question of whether the increased susceptibility of people with neurodegenerative diseases to COVID-19 and poorer outcome may be attributable (at least partly) to biological factors and support a research agenda on this topic. We propose two main putative pathophysiological underpinnings that deserve further investigation: (a) a dysfunction of first barrier mucosal defences, leading to a higher infection rate and (b) a deteriorated, slower immune response to SARS-CoV-2, particularly an impaired T-cell immunity, essential to reduce the severity of the infection and facilitate the recovery of infected individuals. The first hypothesis may be approached by the investigation of the possible role in SARS-CoV-2 infection rates of oropharyngeal dysphagia, common in dementia,^{Reference Rajati, Ahmadi, Naghibzadeh and Kazeminia181} and the effect of reduced salivary lactoferrin levels in Alzheimer's disease, which will reduce the defence mechanisms against SARS-CoV-2 and increase COVID-19 susceptibility.^{Reference Bartolomé, Rosa, Valenti, Lopera, Hernández-Gallego and Cantero189} The second one would require an investigation of the clinical significance of some changes in peripheral blood cell profiles involved at least in Alzheimer's disease and related to inflammation and immune dysfunction, such as the CD4/CD8 ratio,^{Reference Huang, Zhang, Wang and Wang190} which in turn may contribute to severe COVID-19.^{Reference De Zuani, Lazničková, Tomašková, Dvončová, Forte and Stokin191} In addition, individuals homozygous for apolipoprotein E (APOE) ε4 have shown a higher risk of COVID-19-related hospital admission, which could be explained by the changes associated with APOE ε4 that lead to extensive central nervous system inflammation, neurodegeneration and aggressive inflammatory response due to increased blood–brain barrier permeability, exacerbated microglia-mediated neuroinflammation and increased cytokine production in response to inflammatory stimuli.^{Reference Numbers and Brodaty192}

Strength and limitations

This meta-analysis followed MOOSE^{Reference Stroup, Berlin, Morton, Olkin, Williamson and Rennie26} and PRISMA^{Reference Moher, Liberati, Tetzlaff and Altman27} guidelines. In addition, a review protocol was pre-registered with the PROSPERO database. In support of the open science movement to promote transparency, expand access and broaden the range of research output, all the extracted data are openly available at the Open Science Framework (OSF). A further key strength of the study is the inclusion of independent data, which is a crucial assumption in meta-analysis.^{Reference Cheung193} Given that most of the conducted research on the topic of interest is based on freely accessible electronic data-sets, overlapping data-sets were anticipated. Hence, we carefully followed an inclusion protocol, ensuring that no duplicate data were used in each meta-analysis. To achieve this, we ran analyses for both local and nationwide data, and reported similarities or differences among the analyses. An additional strength of the study is the composition of the data-sets. We reported on several outcomes stratified by type of neurodegenerative disease. Last, our study makes use of both frequentist and Bayesian methods. Using this enhanced methodology in our meta-analysis enabled the collection of more exhaustive and reliable data regarding the association between various types of pre-existing neurodegenerative disease and SARS-CoV-2 susceptibility, course and outcome. In this meta-analysis both the frequentist and the Bayesian method showed comparable results, which suggests consistency and overall robustness of the findings.

Aside from these strengths, several limitations need to be considered. First, most of the meta-analyses revealed high between-study heterogeneity which remained unexplained, and publication bias was found in associations between dementia and COVID-19 severity and mortality. Three of the analyses had a small number of studies (fewer than 10) and were difficult to interpret and thought to be unreliable. Accounting for this by means of trim-and-fill methods did not result in different estimates. For the analyses on the associations between dementia and mortality and between mixed dementia and mortality, the trim-and-fill yielded slightly smaller yet significant effect-size estimates (funnel plots and trim-and-fill analyses can be found in the supplementary material). The number of studies for certain outcomes and disease types was relatively small, which may have resulted in high levels of between-study heterogeneity.^{Reference von Hippel194} However, this could also be attributed to the scarce reporting on potential sources of heterogeneity (such as diagnostic criteria, time frame of diagnostic assessment, type of analysis used) in the majority of studies. Consequently, inadequate reporting limited the ability to examine the effect of these sources by running subgroup analyses, sensitivity analyses or meta-regression. Moreover, primary studies that specified subgroups of neurodegenerative disorders reported effect estimates for each category using the entire sample, rather than by subsample. We were therefore unable to pool all effect estimates for some disease types. The Cochrane handbook advises that results derived from meta-regression should be interpreted only when there are >10 studies available per analysis.^{Reference Higgins and Thomas195} Sometimes we reported results based on fewer studies. Last, we cannot attribute causality to the relationships we reported on as all studies were observational and most retrospective.

Implications

Our findings underline the importance of vaccine priority and health surveillance in people with pre-existing neurodegenerative disease, in the current and possibly a next pandemic.

Supplementary material

Supplementary material for this article is available at https://doi.org/10.1192/bjp.2023.43.

Data availability

The data that support the findings of this study are openly available on the Open Science Framework (OSF) at https://osf.io/fz5j4/?view_only=95054452816442eaa1e05d5d42be4b2e

Acknowledgements

We thank Soldevila et al (2022), Secnik et al (2023) and Taquet et al (2021), who, on request, responded on our queries and/or provided additional data.

Author contributions

M.S. and M.L.M. had full access to all data in the study and take responsibility for the integrity of the data and the accuracy of data analyses. All authors were responsible for the study concept and design. M.S., Y.S., M.K. and M.L.M. contributed to the collecting and processing of the data. M.S. and M.L.M. ran all statistical analyses. M.S., M.K., G.R., P.M. and M.L.M. drafted the manuscript. All authors interpreted and discussed the findings. All authors critically revised the manuscript. All authors agreed on the final manuscript and the decision to submit it for publication.

Funding

This research received no specific grant from any funding agency, commercial or not-for-profit sectors.

Declaration of interest

Without relevance to this work, P.M. reports research grants from the Ministry of Education (Spain), the Government of Navarra (Spain), the Spanish Foundation of Psychiatry and Mental Health, and AstraZeneca; he is a clinical consultant for MedAvante-ProPhase and has received lecture honoraria from and/or has been a consultant for AB-Biotics, Adept Field Solutions, Guidepoint, Janssen, Novumed, Roland Berger and Scienta.

References

John, A, Ali, K, Marsh, H, Reddy, PH. Can healthy lifestyle reduce disease progression of Alzheimer's during a global pandemic of COVID-19. Ageing Res Rev 2021; 70: 101406.CrossRef Google Scholar PubMed

Liu, N, Sun, J, Wang, X, Zhao, M, Huang, Q, Li, H. The impact of dementia on the clinical outcome of COVID-19: a systematic review and meta-analysis. J Alzheimers Dis 2020; 78: 1775–82.10.3233/JAD-201016CrossRef Google Scholar PubMed

El-Sadr, WM, Vasan, A, El-Mohandes, A. Facing the new Covid-19 reality. N Engl J Med 2023; 388: 385–7.10.1056/NEJMp2213920CrossRef Google Scholar PubMed

Chojnicki, M, Neumann-Podczaska, A, Seostianin, M, Tomczak, Z, Tariq, H, Chudek, J, et al. Long-term survival of older patients hospitalized for COVID-19: do clinical characteristics upon admission matter?. Int J Environ Res Public Health 2021; 18: 10671.CrossRef Google Scholar PubMed

CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19) - United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 343–6.CrossRef Google Scholar

Bulut, C, Kato, Y. Epidemiology of COVID-19. Turk J Med Sci 2020; 50: 563–70.CrossRef Google Scholar PubMed

Bunn, F, Burn, AM, Goodman, C, Rait, G, Norton, S, Robinson, L, et al. Comorbidity and dementia: a scoping review of the literature. BMC Med 2014; 12: 192.CrossRef Google Scholar PubMed

Holder, K, Reddy, PH. The COVID-19 effect on the immune system and mitochondrial dynamics in diabetes, obesity, and dementia. Neuroscientist 2021; 27: 331–9.CrossRef Google Scholar PubMed

Petrilli, CM, Jones, SA, Yang, J, Rajagopalan, H, O'Donnell, L, Chernyak, Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ 2020; 369: m1966.CrossRef Google Scholar PubMed

Alzheimer's Association. 2022 Alzheimer's disease facts and figures. Alzheimers Dement 2022; 18: 700–89.10.1002/alz.12638CrossRef Google Scholar

Wu, KM, Zhang, YR, Huang, YY, Dong, Q, Tan, L, Yu, JT. The role of the immune system in Alzheimer's disease. Ageing Res Rev 2021; 70: 101409.CrossRef Google Scholar PubMed

Chung, SJ, Chang, Y, Jeon, J, Shin, JI, Song, TJ, Kim, J. Association of Alzheimer's disease with COVID-19 susceptibility and severe complications: a nationwide cohort study. J Alzheimers Dis 2022; 87: 701–10.CrossRef Google Scholar PubMed

Suleyman, G, Fadel, RA, Malette, KM, Hammond, C, Abdulla, H, Entz, A, et al. Clinical characteristics and morbidity associated with coronavirus disease 2019 in a series of patients in metropolitan Detroit. JAMA Netw Open 2020; 3: e2012270.CrossRef Google Scholar

Lutshumba, J, Nikolajczyk, BS, Bachstetter, AD. Dysregulation of systemic immunity in aging and dementia. Front Cell Neurosci 2021; 15: 652111.CrossRef Google Scholar PubMed

Shi, M, Li, C, Tian, X, Chu, F, Zhu, J. Can control infections slow down the progression of Alzheimer's disease? talking about the role of infections in Alzheimer's disease. Front Aging Neurosci 2021; 13: 685863.CrossRef Google Scholar PubMed

Shi, M, Chu, F, Tian, X, Aerqin, Q, Zhu, F, Zhu, J. Role of adaptive immune and impacts of risk factors on adaptive immune in Alzheimer's disease: are immunotherapies effective or off-target. Neuroscientist 2022; 28: 254–70.CrossRef Google Scholar PubMed

Bianchetti, A, Rozzini, R, Bianchetti, L, Coccia, F, Guerini, F, Trabucchi, M. Dementia clinical care in relation to COVID-19. Curr Treat Options Neurol 2022; 24: 1–15.10.1007/s11940-022-00706-7CrossRef Google Scholar PubMed

Azarpazhooh, MR, Amiri, A, Morovatdar, N, Steinwender, S, Rezaei Ardani, A, Yassi, N, et al. Correlations between COVID-19 and burden of dementia: an ecological study and review of literature. J Neurol Sci 2020; 416: 117013.CrossRef Google Scholar PubMed

Shea, YF, Wan, WH, Chan, MMK, DeKosky, ST. Time-to-change: dementia care in COVID -19. Psychogeriatrics 2020; 20: 792–3.CrossRef Google Scholar PubMed

Butler, MJ, Barrientos, RM. The impact of nutrition on COVID-19 susceptibility and long-term consequences. Brain Behav Immun 2020; 87: 53–4.CrossRef Google Scholar PubMed

Alves, VP, Casemiro, FG, Araujo, BG, Lima, MAS, Oliveira, RS, Fernandes, FTS, et al. Factors associated with mortality among elderly people in the COVID-19 pandemic (SARS-CoV-2): a systematic review and meta-analysis. Int J Environ Res Public Health 2021; 18: 8008.10.3390/ijerph18158008CrossRef Google Scholar PubMed

Broad, WJ. The publishing game: getting more for less. Science 1981; 211: 1137–9.CrossRef Google Scholar PubMed

Glasziou, PP, Sanders, S, Hoffmann, T. Waste in covid-19 research. BMJ 2020; 369: m1847.CrossRef Google Scholar PubMed

Treskova-Schwarzbach, M, Haas, L, Reda, S, Pilic, A, Borodova, A, Karimi, K, et al. Pre-existing health conditions and severe COVID-19 outcomes: an umbrella review approach and meta-analysis of global evidence. BMC Med 2021; 19: 212.CrossRef Google Scholar PubMed

von Elm, E, Poglia, G, Walder, B, Tramèr, MR. Different patterns of duplicate publication: an analysis of articles used in systematic reviews. JAMA 2004; 291: 974–80.10.1001/jama.291.8.974CrossRef Google Scholar PubMed

Stroup, DF, Berlin, JA, Morton, SC, Olkin, I, Williamson, GD, Rennie, D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 2000; 283: 2008–12.CrossRef Google Scholar PubMed

Moher, D, Liberati, A, Tetzlaff, J, Altman, DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.CrossRef Google Scholar PubMed

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM-IV). APA, 1994.Google Scholar

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (5th edn) (DSM-5). APA, 2013.Google Scholar

World Health Organization. ICD-10: International Statistical Classification of Diseases and Related Health Problems. WHO, 1992.Google Scholar

Davies, HT, Crombie, IK, Tavakoli, M. When can odds ratios mislead?. BMJ 1998; 316: 989–91.10.1136/bmj.316.7136.989CrossRef Google Scholar PubMed

Grant, RL. Converting an odds ratio to a range of plausible relative risks for better communication of research findings. BMJ 2014; 348: f7450.CrossRef Google Scholar PubMed

Zhang, J, Yu, KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 1998; 280: 1690–1.10.1001/jama.280.19.1690CrossRef Google Scholar PubMed

National Institutes of Health. Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies. NIH, 2021 (https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools).Google Scholar

Sterne, JA, Bradburn, MJ, Egger, M. Meta–Analysis in StataTM, Systematic Reviews in Health Care: Meta-Analysis in Context. John Wiley & Sons, 2001: 347–69.10.1002/9780470693926.ch18CrossRef Google Scholar

Ajayi, B, Trompeter, A, Arnander, M, Sedgwick, P, Lui, DF. 40 days and 40 nights: clinical characteristics of major trauma and orthopaedic injury comparing the incubation and lockdown phases of COVID-19 infection. Bone Joint Open 2020; 1: 330–8.CrossRef Google Scholar PubMed

Beobide Telleria, I, Ferro Uriguen, A, Laso Lucas, E, Sannino Menicucci, C, Enriquez Barroso, M, López de Munain Arregui, A. Risk factors associated with COVID-19 infection and mortality in nursing homes. Aten Primaria 2022; 54: 102463.CrossRef Google Scholar PubMed

Castilla, J, Guevara, M, Miqueleiz, A, Baigorria, F, Ibero-Esparza, C, Navascues, A, et al. Risk factors of infection, hospitalization and death from SARS-CoV-2: a population-based cohort study. J Clin Med 2021; 10(12): 2608.10.3390/jcm10122608CrossRef Google Scholar PubMed

de Malherbe, A, Verdun, S, Brenière, V, Luquel, L, Jourdan, M, Harboun, M. COVID-19 prevalence in UNIVI group nursing homes and multilevel geriatric hospitals: epidemiological study of immunological status with rapid serological tests for diagnostic guidance and follow up. J Nutr Health Aging 2022; 26: 477–84.CrossRef Google Scholar PubMed

Del Ser, T, Fernández-Blázquez, MA, Valentí, M, Zea-Sevilla, MA, Frades, B, Alfayate, E, et al. Residence, clinical features, and genetic risk factors associated with symptoms of COVID-19 in a cohort of older people in Madrid. Gerontology 2021; 67: 281–9.CrossRef Google Scholar

Emmerson, C, Hollinghurst, J, North, L, Fry, R, Akbari, A, Humphreys, C, et al. The impact of dementia, frailty and care home characteristics on SARS-CoV-2 incidence in a national cohort of Welsh care home residents during a period of high community prevalence. Age Ageing 2022; 51(12): afac250.10.1093/ageing/afac250CrossRef Google Scholar

Karapetyan, S, Schneider, A, Linde, K, Donnachie, E, Hapfelmeier, A. SARS-CoV-2 infection and cardiovascular or pulmonary complications in ambulatory care: a risk assessment based on routine data. PLoS ONE 2021; 16: e0258914.CrossRef Google Scholar PubMed

Kim, J, Park, SH, Kim, JM. Effect of comorbidities on the infection rate and severity of COVID-19: nationwide cohort study with propensity score matching. JMIR Public Health Surveill 2022; 8: e35025.CrossRef Google Scholar PubMed

Orlando, V, Rea, F, Savare, L, Guarino, I, Mucherino, S, Perrella, A, et al. Development and validation of a clinical risk score to predict the risk of SARS-CoV-2 infection from administrative data: a population-based cohort study from Italy. PLoS One 2021; 16(1): e0237202.10.1371/journal.pone.0237202CrossRef Google Scholar

Pan, AP, Meeks, J, Potter, T, Masdeu, JC, Seshadri, S, Smith, ML, et al. SARS-CoV-2 susceptibility and COVID-19 mortality among older adults with cognitive impairment: cross-sectional analysis from hospital records in a diverse US metropolitan area. Front Neurol 2021; 12: 692662.10.3389/fneur.2021.692662CrossRef Google Scholar

Profili, F, Ballo, P, Balzi, D, Bellini, B, Bartalocci, S, Zuppiroli, A, et al. Chronic diseases and risk of symptomatic COVID-19: results of a case-population study on a sample of patients in the local health unit ‘Toscana Centro’ (Tuscany Region, Central Italy). Epidemiol Prev 2020; 44: 308–14.Google Scholar

Scherbaum, R, Kwon, EH, Richter, D, Bartig, D, Gold, R, Krogias, C, et al. Clinical profiles and mortality of COVID-19 in patients with Parkinson's disease in Germany. Mov Disord 2021; 36: 1049–57.CrossRef Google Scholar PubMed

Smith, J, Aboumrad, M, Reyes, C, Satram, S, Young-Xu, Y. Predictors of incident severe acute respiratory syndrome coronavirus 2 positivity in a veteran population. Mil Med [Epub ahead of print] 20 Oct 2021. Available from: https://doi.org/10.1093/milmed/usab428.Google Scholar

Seon, JY, Kim, S, Hong, M, Lim, MK, Oh, IH. Risk of COVID-19 diagnosis and death in patients with mental illness: a cohort study. Epidemiol Psychiatr Sci 2021; 30: e68.CrossRef Google Scholar PubMed

Soldevila, L, Prat, N, Mas, MÀ, Massot, M, Miralles, R, Bonet-Simó, JM, et al. The interplay between infection risk factors of SARS-CoV-2 and mortality: a cross-sectional study from a cohort of long-term care nursing home residents. BMC Geriatr 2022; 22: 123.10.1186/s12877-022-02779-0CrossRef Google Scholar PubMed

Tahira, AC, Verjovski-Almeida, S, Ferreira, ST. Dementia is an age-independent risk factor for severity and death in COVID-19 inpatients. Alzheimers Dement 2021; 11: 1818–31.10.1002/alz.12352CrossRef Google Scholar

Wang, Q, Davis, PB, Gurney, ME, Xu, R. COVID-19 and dementia: analyses of risk, disparity, and outcomes from electronic health records in the US. Alzheimers Dement 2021; 17: 1297–306.10.1002/alz.12296CrossRef Google Scholar PubMed

Wang, SM, Park, SH, Kim, NY, Kang, DW, Na, HR, Um, YH, et al. Association between dementia and clinical outcome after COVID-19: a nationwide cohort study with propensity score matched control in South Korea. Psychiatry Investig 2021; 18: 523–9.CrossRef Google Scholar PubMed

Wang, Y, Yang, Y, Ren, L, Shao, Y, Tao, W, Dai, XJ. Preexisting mental disorders increase the risk of COVID-19 infection and associated mortality. Front Public Health 2021; 9: 684112.CrossRef Google Scholar PubMed

Wong, R, Lovier, MA. Relationship between dementia, COVID-19 risk, and adherence to COVID-19 mitigation behaviors among older adults in the United States. Int J Geriatr Psychiatry 2022; 37(6): doi:10.1002/gps.5735.CrossRef Google Scholar PubMed

Worcel, A, Ali, BM, Ramos-Pascual, S, Stirling, P, Chary, FG. Low mortality from COVID-19 at a nursing facility in France following a combined preventive and active treatment protocol. Ann Palliat Med 2021; 10: 11288–300.CrossRef Google Scholar

Yu, YZ, Travaglio, M, Popovic, R, Leal, NS, Martins, LM. Alzheimer's and Parkinson's diseases predict different COVID-19 outcomes: a UK Biobank study. Geriatrics 2021; 6(1): 10.CrossRef Google Scholar PubMed

Zenesini, C, Vignatelli, L, Belotti, LMB, Baccari, F, Calandra-Buonaura, G, Cortelli, P, et al. Risk of SARS-CoV-2 infection, hospitalization and death for COVID-19 in people with Parkinson's disease or parkinsonism over a 15-month period: a cohort study. Eur J Neurol [Epub ahead of print] 16 Jul 2022. Available from: https://doi.org/10.1111/ene.15505.CrossRef Google Scholar PubMed

Zhou, J, Liu, C, Sun, Y, Huang, W, Ye, K. Cognitive disorders associated with hospitalization of COVID-19: results from an observational cohort study. Brain Behav Immun Health 2021; 91: 383–92.CrossRef Google Scholar PubMed

Ajayi, B, Trompeter, AJ, Umarji, S, Saha, P, Arnander, M, Lui, DF. Catching the second wave: clinical characteristics and nosocomial infection rates in major trauma and orthopaedic patients during the COVID-19 pandemic. Bone Jt Open 2021; 2: 661–70.CrossRef Google Scholar PubMed

Alqahtani, AM, Alshahrani, FM, Khalaf, MME, Rezk, SR. Outcome of COVID-19 among homecare patients and its relation to chronic diseases. World Family Med 2021; 19: 111–7.Google Scholar

An, C, Oh, HC, Chang, JH, Oh, SJ, Lee, JM, Han, CH, et al. Development and validation of a prognostic model for early triage of patients diagnosed with COVID-19. Sci Rep 2021; 11: 21923.CrossRef Google Scholar PubMed

Atkins, JL, Masoli, JAH, Delgado, J, Pilling, LC, Kuo, CL, Kuchel, GA, et al. Preexisting comorbidities predicting COVID-19 and mortality in the UK Biobank community cohort. J Gerontol A Biol Sci Med Sci 2020; 75: 2224–30.CrossRef Google Scholar PubMed

Bae, S, Kim, Y, Hwang, S, Kwon, KT, Chang, HH, Kim, SW. New scoring system for predicting mortality in patients with COVID-19. Yonsei Med J 2021; 62: 806–13.CrossRef Google Scholar PubMed

Baker, SM, Leedy, DJ, Klafter, JA, Zhang, Y, Secrest, KM, Osborn, TR, et al. Clinical presentation, complications, and outcomes of hospitalized COVID-19 patients in an academic center with a centralized palliative care consult service. Health Sci Rep 2021; 4: e423.CrossRef Google Scholar

Banoei, MM, Dinparastisaleh, R, Zadeh, AV, Mirsaeidi, M. Machine-learning-based COVID-19 mortality prediction model and identification of patients at low and high risk of dying. Crit Care 2021; 25: 328.CrossRef Google Scholar PubMed

Becerra-Muñoz, VM, Núñez-Gil, IJ, Eid, CM, García Aguado, M, Romero, R, Huang, J, et al. Clinical profile and predictors of in-hospital mortality among older patients hospitalised for COVID-19. Age Ageing 2021; 50: 326–34.CrossRef Google Scholar PubMed

Bennett, TD, Moffitt, RA, Hajagos, JG, Amor, B, Anand, A, Bissell, MM, et al. Clinical characterization and prediction of clinical severity of SARS-CoV-2 infection among US adults using data from the US national COVID cohort collaborative. JAMA Netw Open 2021; 4(7): e2116901.CrossRef Google Scholar PubMed

Bhargava, A, Szpunar, SM, Sharma, M, Fukushima, EA, Hoshi, S, Levine, M, et al. Clinical features and risk factors for in-hospital mortality from COVID-19 infection at a tertiary care medical center, at the onset of the US COVID-19 pandemic. J Intensive Care Med 2021; 36: 711–8.CrossRef Google Scholar

Bianchetti, A, Rozzini, R, Guerini, F, Boffelli, S, Ranieri, P, Minelli, G, et al. Clinical presentation of COVID19 in dementia patients. J Nutr Health Aging 2020; 24: 560–2.CrossRef Google Scholar PubMed

Bielza, R, Sanz, J, Zambrana, F, Arias, E, Malmierca, E, Portillo, L, et al. Clinical characteristics, frailty, and mortality of residents with COVID-19 in nursing homes of a region of Madrid. J Am Med Dir Assoc 2021; 22: 245–252.e2.CrossRef Google Scholar PubMed

Booij, JA, van de Haterd, J, Huttjes, SN, van Deijck, R, Koopmans, R. Short- and long-term mortality and mortality risk factors among nursing home patients after COVID-19 infection. J Am Med Dir Assoc 2022; 23: 1274–8.CrossRef Google Scholar

Boye, KS, Tokar Erdemir, E, Zimmerman, N, Reddy, A, Benneyworth, BD, Dabora, MC, et al. Risk factors associated with COVID-19 hospitalization and mortality: a large claims-based analysis among people with type 2 diabetes mellitus in the United States. Diabetes Ther 2021; 12: 2223–39.CrossRef Google Scholar PubMed

Bucholc, M, Bradley, D, Bennett, D, Patterson, L, Spiers, R, Gibson, D, et al. Identifying pre-existing conditions and multimorbidity patterns associated with in-hospital mortality in patients with COVID-19. Sci Rep 2022; 12: 17313.CrossRef Google Scholar PubMed

Busetto, L, Bettini, S, Fabris, R, Serra, R, Dal Pra, C, Maffei, P, et al. Obesity and COVID-19: an Italian snapshot. Obesity 2020; 28: 1600–5.10.1002/oby.22918CrossRef Google Scholar PubMed

Caliskan, T, Saylan, B. Smoking and comorbidities are associated with COVID-19 severity and mortality in 565 patients treated in Turkey: a retrospective observational study. Rev Assoc Med Bras 2020; 66: 1679–84.CrossRef Google Scholar PubMed

Carrillo-Garcia, P, Garmendia-Prieto, B, Cristofori, G, Montoya, IL, Hidalgo, JJ, Feijoo, MQ, et al. Health status in survivors older than 70 years after hospitalization with COVID-19: observational follow-up study at 3 months. Eur Geriatr Med 2021; 12: 1091–4.10.1007/s41999-021-00516-1CrossRef Google Scholar PubMed

Chang, MH, Moonesinghe, R, Truman, BI. COVID-19 hospitalization by race and ethnicity: association with chronic conditions among Medicare beneficiaries, January 1-September 30, 2020. J Racial Ethnic Health Disparities 2022; 9(1): 325–34.CrossRef Google Scholar PubMed

Chatterjee, A, Wu, GY, Primakov, S, Oberije, C, Woodruff, H, Kubben, P, et al. Can predicting COVID-19 mortality in a European cohort using only demographic and comorbidity data surpass age-based prediction: an externally validated study. PLoS One 2021; 16(4): e0249920.10.1371/journal.pone.0249920CrossRef Google Scholar

Chen, UI, Xu, H, Krause, TM, Greenberg, R, Dong, X, Jiang, X. Factors associated with COVID-19 death in the United States: cohort study. JMIR Public Health Surveill 2022; 8: e29343.CrossRef Google Scholar PubMed

Choi, YJ, Park, JY, Lee, HS, Suh, J, Song, JY, Byun, MK, et al. Variable effects of underlying diseases on the prognosis of patients with COVID-19. PLoS One 2021; 16(7): e0254258.10.1371/journal.pone.0254258CrossRef Google Scholar PubMed

Chojnicki, M, Neumann-Podczaska, A, Seostianin, M, Tomczak, Z, Tariq, H, Chudek, J, et al. Long-term survival of older patients hospitalized for COVID-19: Do clinical characteristics upon admission matter?. Int J Environ Res Public Health 2021; 18(20): 10671.CrossRef Google Scholar PubMed

Cisterna-García, A, Guillén-Teruel, A, Caracena, M, Pérez, E, Jiménez, F, Francisco-Verdú, FJ, et al. A predictive model for hospitalization and survival to COVID-19 in a retrospective population-based study. Sci Rep 2022; 12: 18126.CrossRef Google Scholar

COVIDSurg Collaborative. Outcomes after perioperative SARS-CoV-2 infection in patients with proximal femoral fractures: an international cohort study. BMJ Open 2021; 11: e050830.CrossRef Google Scholar

Covino, M, De Matteis, G, Santoro, M, Sabia, L, Simeoni, B, Candelli, M, et al. Clinical characteristics and prognostic factors in COVID-19 patients aged ≥80 years. Geriatr Gerontol Int 2020; 20: 704–8.10.1111/ggi.13960CrossRef Google Scholar PubMed

Covino, M, De Matteis, G, Polla, DAD, Santoro, M, Burzo, ML, Torelli, E, et al. Predictors of in-hospital mortality and death risk stratification among COVID-19 patients aged ≥ 80 years old. Arch Gerontol Geriatr 2021; 95: 104383.CrossRef Google Scholar PubMed

Covino, M, Russo, A, Salini, S, De Matteis, G, Simeoni, B, Della Polla, D, et al. Frailty assessment in the emergency department for risk stratification of COVID-19 patients aged ≥80 years. J Am Med Dir Assoc 2021; 22: 1845–1852.e1.CrossRef Google Scholar PubMed

Cummins, L, Ebyarimpa, I, Cheetham, N, Tzortziou Brown, V, Brennan, K, Panovska-Griffiths, J. Factors associated with COVID-19 related hospitalisation, critical care admission and mortality using linked primary and secondary care data. Influenza Other Respi Viruses 2021; 15: 577–88.CrossRef Google Scholar PubMed

de Marcaida, JA, Lahrmann, J, Machado, D, Bluth, L, Dagostine, M, Moro-de Casillas, M, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) among patients at a movement disorders center. Geriatrics 2020; 5(3): 54.CrossRef Google Scholar

De Smet, R, Mellaerts, B, Vandewinckele, H, Lybeert, P, Frans, E, Ombelet, S, et al. Frailty and mortality in hospitalized older adults with COVID-19: retrospective observational study. J Am Med Dir Assoc 2020; 21: 928–32.e1.CrossRef Google Scholar PubMed

Descamps, A, Frenkiel, J, Zarca, K, Laidi, C, Godin, O, Launay, O, et al. Association between mental disorders and COVID-19 outcomes among inpatients in France: a retrospective nationwide population-based study. J Psychiatr Res 2022; 155: 194–201.CrossRef Google Scholar

Ellis, RJ, Moffatt, CR, Aaron, LT, Beaverson, G, Chaw, K, Curtis, C, et al. Factors associated with hospitalisations and deaths of residential aged care residents with COVID-19 during the Omicron (BA.1) wave in Queensland. Med J Aust 2023; 218: 174–9.10.5694/mja2.51813CrossRef Google Scholar

Escribà-Salvans, A, Rierola-Fochs, S, Farrés-Godayol, P, Molas-Tuneu, M, Bezerra de Souza, DL, Skelton, DA, et al. Risk factors for developing symptomatic COVID-19 in older residents of nursing homes: A hypothesis-generating observational study. MedRxiv (Preprint] 2022. Available from: https://doi.org/10.1101/2022.01.18.22269433.CrossRef Google Scholar

Esme, M, Koca, M, Dikmeer, A, Balci, C, Ata, N, Dogu, BB, et al. Older adults with coronavirus disease 2019: a nationwide study in Turkey. J Gerontol A Biol Sci Med Sci 2021; 76: e68–75.CrossRef Google Scholar PubMed

España, PP, Bilbao, A, García-Gutiérrez, S, Lafuente, I, Anton-Ladislao, A, Villanueva, A, et al. Predictors of mortality of COVID-19 in the general population and nursing homes. Intern Emerg Med 2021; 16: 1487–96.CrossRef Google Scholar PubMed

Esteban, I, Bergero, G, Alves, C, Bronstein, M, Ziegler, V, Wood, C, et al. Asymptomatic COVID-19 in the elderly: dementia and viral clearance as risk factors for disease progression. Am J Respir Crit Care Med 2021; 203: A3826.Google Scholar

Fasano, A, Cereda, E, Barichella, M, Cassani, E, Ferri, V, Zecchinelli, AL, et al. COVID-19 in Parkinson's disease patients living in Lombardy, Italy. Mov Disord 2020; 35: 1089–93.CrossRef Google Scholar PubMed

Fathi, M, Taghizadeh, F, Mojtahedi, H, Zargar Balaye Jame, S, Markazi Moghaddam, N. The effects of Alzheimer's and Parkinson's disease on 28-day mortality of COVID-19. Rev Neurol (Paris) 2022; 178:129–36.CrossRef Google Scholar PubMed

Filardo, TD, Khan, MR, Krawczyk, N, Galitzer, H, Karmen-Tuohy, S, Coffee, M, et al. Comorbidity and clinical factors associated with COVID-19 critical illness and mortality at a large public hospital in New York City in the early phase of the pandemic (March-April 2020). PLoS One 2020; 15(11): e0242760.CrossRef Google Scholar

Filipe, MS, Maroussia, R, Brian, F, Amaury, T, Anne, I, Alexia, C, et al. Risk factors for severe outcomes for COVID-19 patients hospitalised in Switzerland during the first pandemic wave, February to August 2020: prospective observational cohort study. Swiss Med Wkly 2021; 151: w20547.Google Scholar

Fumagalli, C, Ungar, A, Rozzini, R, Vannini, M, Coccia, F, Cesaroni, G, et al. Predicting mortality risk in older hospitalized persons with COVID-19: a comparison of the COVID-19 mortality risk score with frailty and disability. J Am Med Dir Assoc 2021; 22: 1588–92.e1.CrossRef Google Scholar PubMed

Gale, TM, Boland, B. COVID-19 deaths in a secondary mental health service. Compr Psychiatry 2021; 111: 152277.CrossRef Google Scholar

Ge, E, Li, Y, Wu, S, Candido, E, Wei, X. Association of pre-existing comorbidities with mortality and disease severity among 167,500 individuals with COVID-19 in Canada: a population-based cohort study. PLoS One 2021; 16: e0258154.CrossRef Google Scholar

Genet, B, Vidal, JS, Cohen, A, Boully, C, Beunardeau, M, Marine Harlé, L, et al. COVID-19 in-hospital mortality and use of renin-angiotensin system blockers in geriatrics patients. J Am Med Dir Assoc 2020; 21: 1539–45.CrossRef Google Scholar PubMed

Geriatric Medicine Research Collaborative, COVID Collaborative, Welch C. Age and frailty are independently associated with increased COVID-19 mortality and increased care needs in survivors: results of an international multi-centre study. Age Aging 2021; 50: 617–30.CrossRef Google Scholar

Ghaffari, M, Ansari, H, Beladimoghadam, N, Aghamiri, SH, Haghighi, M, Nabavi, M, et al. Neurological features and outcome in COVID-19: dementia can predict severe disease. J Neurovirol 2021; 27: 86–93.10.1007/s13365-020-00918-0CrossRef Google Scholar PubMed

Gómez Antúnez, M, Muiño Míguez, A, Bendala Estrada, AD, Maestro de la Calle, G, Monge Monge, D, Boixeda, R, et al. Clinical characteristics and prognosis of COPD patients hospitalized with SARS-CoV-2. Int J Chron Obstruct Pulmon Dis 2020; 15: 3433–45.CrossRef Google Scholar PubMed

Harrison, SL, Fazio-Eynullayeva, E, Lane, DA, Underhill, P, Lip, GYH. Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: a federated electronic medical record analysis. PLoS Med 2020; 17(9): e1003321.10.1371/journal.pmed.1003321CrossRef Google Scholar

Hasani Azad, M, Khorrami, F, Kazemi Jahromi, M, Alishan Karami, N, Shahi, M, Davari Dolatabadi, N, et al. clinical and epidemiological characteristics of hospitalized COVID-19 patients in Hormozgan, Iran: a retrospective, multicenter study. Arch Iran Med 2021; 24: 434–44.CrossRef Google Scholar PubMed

Hatamabadi, H, Sabaghian, T, Sadeghi, A, Heidari, K, Safavi-Naini, SAA, Looha, MA, et al. Epidemiology of COVID-19 in Tehran, Iran: a cohort study of clinical profile, risk factors, and outcomes. Biomed Res Int 2022; 2022: 2350063.CrossRef Google Scholar PubMed

Hippisley-Cox, J, Coupland, CA, Mehta, N, Keogh, RH, Diaz-Ordaz, K, Khunti, K, et al. Risk prediction of COVID-19 related death and hospital admission in adults after COVID-19 vaccination: national prospective cohort study. BMJ 2021; 374: n2244.CrossRef Google Scholar PubMed

Hwang, JM, Kim, JH, Park, JS, Chang, MC, Park, D. Neurological diseases as mortality predictive factors for patients with COVID-19: a retrospective cohort study. Neurol Sci 2020; 41: 2317–24.CrossRef Google Scholar PubMed

Izurieta, HS, Graham, DJ, Jiao, Y, Hu, M, Lu, Y, Wu, Y, et al. Natural history of coronavirus disease 2019: risk factors for hospitalizations and deaths among >26 million US Medicare beneficiaries. J Infect Dis 2021; 223: 945–56.CrossRef Google Scholar PubMed

Kang, IS, Kong, KA. Body mass index and severity/fatality from coronavirus disease 2019: a nationwide epidemiological study in Korea. PLoS ONE 2021; 16(6): e0253640.CrossRef Google Scholar PubMed

Ken-Dror, G, Wade, C, Sharma, S, Law, J, Russo, C, Sharma, A, et al. COVID-19 outcomes in UK centre within highest health and wealth band: a prospective cohort study. BMJ Open 2020; 10: e042090.CrossRef Google Scholar PubMed

Kim, SR, Nam, SH, Kim, YR. Risk factors on the progression to clinical outcomes of COVID-19 patients in South Korea: using national data. Int J Environ Res Public Health 2020; 17(23): 8847.Google Scholar PubMed

Kim, SW, Kim, SM, Kim, YK, Kim, JY, Lee, YM, Kim, BO, et al. Clinical characteristics and outcomes of COVID-19 cohort patients in Daegu Metropolitan City outbreak in 2020. J Korean Med Sci 2021; 36: e12.CrossRef Google Scholar PubMed

Kim, J, Blaum, C, Ferris, R, Arcila-Mesa, M, Do, H, Pulgarin, C, et al. Factors associated with hospital admission and severe outcomes for older patients with COVID-19. J Am Geriatr Soc 2022; 70: 1906–17.CrossRef Google Scholar PubMed

Kong, KA, Jung, S, Yu, M, Park, J, Kang, IS. Association between cardiovascular risk factors and the severity of coronavirus disease 2019: nationwide epidemiological study in Korea. Front Cardiovasc Med 2021; 8: 732518.CrossRef Google Scholar PubMed

Kostev, K, Gessler, N, Wohlmuth, P, Arnold, D, Bein, B, Bohlken, J, et al. Is dementia associated with COVID-19 mortality? A multicenter retrospective cohort study conducted in 50 hospitals in Germany. J Alzheimers Dis 2023; 91: 719–26.CrossRef Google Scholar PubMed

Kyoung, DS, Lee, J, Nam, H, Park, MH. Dementia and COVID-19 mortality in South Korea. Dement Neurocogn Disord 2021; 20: 38–40.CrossRef Google Scholar PubMed

Lazcano, U, Cuadrado-Godia, E, Grau, M, Subirana, I, Martínez-Carbonell, E, Boher-Massaguer, M, et al. Increased COVID-19 mortality in people with previous cerebrovascular disease: a population-based cohort study. Stroke 2022; 53: 1276–84.CrossRef Google Scholar PubMed

Li, JW, Long, X, Huang, HQ, Tang, JN, Zhu, CL, Hu, SP, et al. Resilience of Alzheimer's disease to COVID-19. J Alzheimers Dis 2020; 77: 67–73.CrossRef Google Scholar PubMed

Livingston, G, Rostamipour, H, Gallagher, P, Kalafatis, C, Shastri, A, Huzzey, L, et al. Prevalence, management, and outcomes of SARS-CoV-2 infections in older people and those with dementia in mental health wards in London, UK: a retrospective observational study. Lancet Psychiatry 2020; 7: 1054–63.CrossRef Google Scholar PubMed

Lozano-Montoya, I, Quezada-Feijoo, M, Jaramillo-Hidalgo, J, Garmendia-Prieto, B, Lisette-Carrillo, P, Gómez-Pavón, FJ. Mortality risk factors in a Spanish cohort of oldest-old patients hospitalized with COVID-19 in an acute geriatric unit: the OCTA-COVID study. Eur Geriatr Med 2021; 12: 1169–80.CrossRef Google Scholar

Lu, Y, Jiao, Y, Graham, DJ, Wu, Y, Wang, J, Menis, M, et al. Risk factors for COVID-19 deaths among elderly nursing home Medicare beneficiaries in the pre-vaccine period. J Infect Dis 2022; 225: 567–77.CrossRef Google Scholar

Lucijanić, M, Piskač Živković, N, Zelenika, M, Barišić-Jaman, M, Jurin, I, Matijaca, A, et al. Survival after hospital discharge in patients hospitalized for acute coronavirus disease 2019: data on 2586 patients from a tertiary center registry. Croat Med J 2022; 63: 335–42.CrossRef Google Scholar PubMed

Magallon-Botaya, R, Olivan-Blazquez, B, Ramirez-Cervantes, KL, Mendez-Lopez-de-la-Manzanara, F, Aguilar-Palacio, I, Casajuana-Closas, M, et al. Geographic factors associated with poorer outcomes in patients diagnosed with COVID-19 in primary health care. Int J Environ Res Public Health 2021; 18(7): 3842.CrossRef Google Scholar PubMed

Maguire, D, Woods, M, Richards, C, Dolan, R, Veitch, JW, Sim, WMJ, et al. Prognostic factors in patients admitted to an urban teaching hospital with COVID-19 infection. J Transl Med 2020; 18(1): 354.CrossRef Google Scholar

Mahmoud, M, Carmisciano, L, Tagliafico, L, Muzyka, M, Rosa, G, Signori, A, et al. Patterns of comorbidity and in-hospital mortality in older patients with COVID-19 infection. Front Med (Lausanne) 2021; 8: 726837.CrossRef Google Scholar PubMed

Maniero, C, Patel, D, Pavithran, A, Naran, P, Ng, FL, Prowle, J, et al. A retrospective cohort study of risk factors and outcomes in older patients admitted to an inner-city geriatric unit in London during first peak of COVID-19 pandemic. Ir J Med Sci 2022; 191: 1037–45.CrossRef Google Scholar

Martinot, M, Eyriey, M, Gravier, S, Bonijoly, T, Kayser, D, Ion, C, et al. Predictors of mortality, ICU hospitalization, and extrapulmonary complications in COVID-19 patients. Infect Dis Now 2021; 51: 518–25.CrossRef Google Scholar PubMed

Meis-Pinheiro, U, Lopez-Segui, F, Walsh, S, Ussi, A, Santaeugenia, S, Garcia-Navarro, JA, et al. Clinical characteristics of COVID-19 in older adults. a retrospective study in long-term nursing homes in Catalonia. PLoS One 2021; 16(7): e0255141.CrossRef Google Scholar PubMed

Menditto, VG, Fulgenzi, F, Bonifazi, M, Gnudi, U, Gennarini, S, Mei, F, et al. Predictors of readmission requiring hospitalization after discharge from emergency departments in patients with COVID-19. Am J Emerg Med 2021; 46: 146–9.10.1016/j.ajem.2021.04.055CrossRef Google Scholar PubMed

Miyashita, S, Yamada, T, Mikami, T, Miyashita, H, Chopra, N, Rizk, D. Impact of dementia on clinical outcomes in elderly patients with coronavirus 2019 (COVID-19): an experience in New York. Geriatrics & Gerontology International 2020; 20: 732–4.CrossRef Google Scholar PubMed

Molani, S, Hernandez, PV, Roper, RT, Duvvuri, VR, Baumgartner, AM, Goldman, JD, et al. Risk factors for severe COVID-19 differ by age for hospitalized adults. Sci Rep 2022; 12: 6568.10.1038/s41598-022-10344-3CrossRef Google Scholar PubMed

Moon, HJ, Kim, K, Kang, EK, Yang, HJ, Lee, E. Prediction of COVID-19-related mortality and 30-day and 60-day survival probabilities using a nomogram. J Korean Med Sci 2021; 36: e248.CrossRef Google Scholar PubMed

Munblit, D, Nekliudov, NA, Bugaeva, P, Blyuss, O, Kislova, M, Listovskaya, E, et al. Stop COVID Cohort: an observational study of 3480 patients admitted to the Sechenov University Hospital network in Moscow city for suspected coronavirus disease 2019 (COVID-19) infection. Clin Infect Dis 2021; 73: 1–11.CrossRef Google Scholar

Nojiri, S, Irie, Y, Kanamori, R, Naito, T, Nishizaki, Y. Mortality prediction of COVID-19 in hospitalized patients using the 2020 diagnosis procedure combination administrative database of Japan. Intern Med 2023; 62: 201–13.CrossRef Google Scholar PubMed

Oh, H, Kim, R, Chung, W. Sex-specific association between underlying diseases and the severity and mortality due to COVID-19 infection: a retrospective observational cohort analysis of clinical epidemiological information collected by the Korea Disease Control and Prevention Agency. Healthcare (Basel) 2022; 10(10): 1846.Google Scholar PubMed

Ouattara, E, Bruandet, A, Borde, A, Lenne, X, Binder-Foucard, F, Le-Bourhis-Zaimi, M, et al. Risk factors of mortality among patients hospitalised with COVID-19 in a critical care or hospital care unit: analysis of the French national medicoadministrative database. BMJ Open Respir Res 2021; 8(1): e001002.CrossRef Google Scholar PubMed

Panagiotou, OA, Kosar, CM, White, EM, Bantis, LE, Yang, XF, Santostefano, CM, et al. Risk factors associated with all-cause 30-day mortality in nursing home residents with COVID-19. JAMA Int Med 2021; 181: 439–48.CrossRef Google Scholar PubMed

Patel, RA, Stebbins, GT, Kishen, EB, Barton, B. COVID-19 outcomes in hospitalized patients with neurodegenerative disease: a retrospective cohort study. Neurol Clin Pract 2022; 12: 43–51.Google Scholar PubMed

Pisaturo, M, Calò, F, Russo, A, Camaioni, C, Giaccone, A, Pinchera, B, et al. Dementia as risk factor for severe coronavirus disease 2019: a case-control study. Front Aging Neurosci 2021; 13: 698184.CrossRef Google Scholar PubMed

Raheja, H, Chukwuka, N, Agarwal, C, Sharma, D, Munoz-Martinez, A, Fogel, J, et al. Should COVID-19 patients >75 years be ventilated? An outcome study. QJM 2021; 114: 182–9.CrossRef Google Scholar PubMed

Ramos-Rincón, JM, Bernabeu-Whittel, M, Fiteni-Mera, I, López-Sampalo, A, López-Ríos, C, García-Andreu, MDM, et al. Clinical features and risk factors for mortality among long-term care facility residents hospitalized due to COVID-19 in Spain. J Gerontol A Biol Sci Med Sci 2022; 77: e138–47.CrossRef Google Scholar PubMed

Ramos-Rincon, JM, Buonaiuto, V, Ricci, M, Martín-Carmona, J, Paredes-Ruíz, D, Calderón-Moreno, M, et al. Clinical characteristics and risk factors for mortality in very old patients hospitalized with COVID-19 in Spain. J Gerontol A Biol Sci Med Sci 2021; 76: e28–37.CrossRef Google Scholar PubMed

Rebora, P, Rozzini, R, Bianchetti, A, Blangiardo, P, Marchegiani, A, Piazzoli, A, et al. Delirium in patients with SARS-CoV -2 infection: a multicenter study. J Am Geriatr Soc 2021; 69: 293–9.CrossRef Google Scholar PubMed

Roig-Marín, N, Roig-Rico, P. Elderly people with Dementia admitted for COVID-19: how different are they?. Exp Aging Res 2022; 48: 177–90.CrossRef Google Scholar

Romagnolo, A, Balestrino, R, Imbalzano, G, Ciccone, G, Riccardini, F, Artusi, CA, et al. Neurological comorbidity and severity of COVID-19. J Neurol 2021; 268: 762–9.CrossRef Google Scholar PubMed

Romagnolo, A, Imbalzano, G, Artusi, CA, Balestrino, R, Ledda, C, De Rosa, FG, et al. Neurological comorbidities and COVID-19-related case fatality: a cohort study. J Neurol Sci 2021; 428: 117610.CrossRef Google Scholar PubMed

Rossi, PG, Marino, M, Formisano, D, Venturelli, F, Vicentini, M, Grilli, R, et al. Characteristics and outcomes of a cohort of COVID-19 patients in the province of Reggio Emilia, Italy. PLoS One 2020; 15(8): e0238281.Google Scholar

Russo, AG, Decarli, A, Valsecchi, MG. Strategy to identify priority groups for COVID-19 vaccination: a population based cohort study. Vaccine 2021; 39: 2517–25.CrossRef Google Scholar PubMed

Rutten, JJS, van Kooten, J, van Loon, AM, van Buul, LW, Joling, KJ, Smalbrugge, M, et al. Dementia and Parkinson's disease: risk factors for 30-day mortality in nursing home residents with COVID-19. J Alzheimers Dis 2021; 84: 1173–81.CrossRef Google Scholar PubMed

Salari, M, Etemadifar, M, Ashrafi, F, Ommi, D, Aminzade, Z, Tehrani Fateh, S. Parkinson's disease patients may have higher rates of Covid-19 mortality in Iran. Parkinsonism Relat Disord 2021; 89: 90–2.CrossRef Google Scholar PubMed

Samuels, S, Niu, J, Sareli, C, Eckardt, P. The epidemiology and predictors of outcomes among confirmed COVID-19 cases in a large community healthcare system in South Florida. J Community Health 2021; 46: 822–31.CrossRef Google Scholar

Secnik, J, Eriksdotter, M, Xu, H, Annetorp, M, Rytarowski, A, Johnell, K, et al. Dementia and psychotropic medications are associated with significantly higher mortality in geriatric patients hospitalized with COVID-19: data from the StockholmGeroCovid project. Alzheimers Res Ther 2023; 15: 5.CrossRef Google Scholar PubMed

Shin, EK, Choi, HY, Hayes, N. The anatomy of COVID-19 comorbidity networks among hospitalized Korean patients. Epidemiol Health 2021; 43: e2021035.CrossRef Google Scholar PubMed

Song, J, Park, DW, Cha, JH, Seok, H, Kim, JY, Park, J, et al. Clinical course and risk factors of fatal adverse outcomes in COVID-19 patients in Korea: a nationwide retrospective cohort study. Sci Rep 2021; 11(1): 10066.Google Scholar PubMed

Stawinski, PM, Dziadkowiec, KN, Al-Abbasi, B, Suarez, L, Simms, L, Dewaswala, N, et al. Model of end-stage liver disease (MELD) score as a predictor of in-hospital mortality in patients with COVID-19: a novel approach to a classic scoring system. Cureus 2021; 13: e15179.Google Scholar PubMed

Tsai, A, Diawara, O, Nahass, RG, Brunetti, L. Impact of tocilizumab administration on mortality in severe COVID-19. Sci Rep 2020; 10(1): 19131.CrossRef Google Scholar PubMed

Tyson, B, Erdodi, L, Shahein, A, Kamrun, S, Eckles, M, Agarwal, P. Predictors of survival in older adults hospitalized with COVID-19. Neurol Sci 2021; 42: 3953–8.CrossRef Google Scholar PubMed

Vekaria, PH, Syed, A, Anderson, J, Cornett, B, Bourbia, A, Flynn, MG, et al. Association of dementia and patient outcomes among COVID-19 patients: a multi-center retrospective case-control study. Front Med (Lausanne) 2022; 9: 1050747.CrossRef Google Scholar PubMed

Venturini, S, Orso, D, Cugini, F, Crapis, M, Fossati, S, Callegari, A, et al. Classification and analysis of outcome predictors in non-critically ill COVID-19 patients. Intern Med J 2021; 51: 506–14.CrossRef Google Scholar PubMed

Vignatelli, L, Zenesini, C, Belotti, LMB, Baldin, E, Bonavina, G, Calandra-Buonaura, G, et al. Risk of hospitalization and death for COVID-19 in people with Parkinson's disease or Parkinsonism. Mov Disord 2021; 36: 1–10.CrossRef Google Scholar PubMed

Wan, Y, Wu, J, Ni, LH, Luo, QQ, Yuan, C, Fan, F, et al. Prognosis analysis of patients with mental disorders with COVID-19: a single-center retrospective study. Aging-Us 2020; 12: 11238–44.CrossRef Google Scholar PubMed

Yakar, MN, Ergan, B, Ergün, B, Küçük, M, Cantürk, A, Ergon, MC, et al. Clinical characteristics and risk factors for 28-day mortality in critically ill patients with COVID-19: a retrospective cohort study. Turk J Med Sci 2021; 51: 2285–95.CrossRef Google Scholar PubMed

Zakaria, A, Piper, M, Douda, L, Jackson, NM, Flynn, JC, Misra, DP, et al. Determinants of all-cause in-hospital mortality among patients who presented with COVID-19 to a community teaching hospital in Michigan. Heliyon 2021; 7(12): e08566.CrossRef Google Scholar PubMed

Zerbo, O, Lewis, N, Fireman, B, Goddard, K, Skarbinski, J, Sejvar, JJ, et al. Population-based assessment of risks for severe COVID-19 disease outcomes. Influenza Other Respir Viruses 2022; 16: 159–65.CrossRef Google Scholar PubMed

Zhang, Q, Schultz, JL, Aldridge, GM, Simmering, JE, Kim, Y, Ogilvie, AC, et al. COVID-19 case fatality and Alzheimer's disease. J Alzheimers Dis 2021; 84: 1447–52.CrossRef Google Scholar PubMed

Zhou, JD, Lee, S, Wang, XS, Li, Y, Wu, WKK, Liu, T, et al. Development of a multivariable prediction model for severe COVID-19 disease: a population-based study from Hong Kong. NPJ Digital Medicine 2021; 4(1): 66.CrossRef Google Scholar PubMed

Bellou, V, Tzoulaki, I, van Smeden, M, Moons, KGM, Evangelou, E, Belbasis, L. Prognostic factors for adverse outcomes in patients with COVID-19: a field-wide systematic review and meta-analysis. Eur Respir J 2022; 59: 2002964.CrossRef Google Scholar PubMed

Wang, M, Baker, JS, Quan, W, Shen, S, Fekete, G, Gu, Y. A preventive role of exercise across the coronavirus 2 (SARS-CoV-2) Pandemic. Front Physiol 2020; 11: 572718.CrossRef Google Scholar PubMed

Nikolich-Zugich, J, Knox, KS, Rios, CT, Natt, B, Bhattacharya, D, Fain, MJ. SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes. Geroscience 2020; 42: 505–14.CrossRef Google Scholar PubMed

Harris-Kojetin, L, Sengupta, M, Park-Lee, E, Valverde, R, Caffrey, C, Rome, V, et al. Long-term care providers and services users in the United States: data from the national study of long-term care providers, 2013–2014. Vital Health Stat 3 2016; (38): x–xii.Google Scholar PubMed

Cagnin, A, Di Lorenzo, R, Marra, C, Bonanni, L, Cupidi, C, Laganà, V, et al. Behavioral and psychological effects of coronavirus disease-19 quarantine in patients with dementia. Stat Med 2020; 11: 578015.Google Scholar PubMed

Bayati, M. Why is COVID-19 more concentrated in countries with high economic status?. Iran J Public Health 2021; 50: 1926–9.Google Scholar PubMed

Statsenko, Y, Al Zahmi, F, Habuza, T, Almansoori, TM, Smetanina, D, Simiyu, GL, et al. Impact of age and sex on COVID-19 severity assessed from radiologic and clinical findings. Front Cell Infect Microbiol 2021; 11: 777070.CrossRef Google Scholar PubMed

Dadras, O, SeyedAlinaghi, S, Karimi, A, Shamsabadi, A, Qaderi, K, Ramezani, M, et al. COVID-19 mortality and its predictors in the elderly: a systematic review. Health Sci Rep 2022; 5: e657.CrossRef Google Scholar PubMed

Putri, C, Hariyanto, TI, Hananto, JE, Christian, K, Situmeang, RFV, Kurniawan, A. Parkinson's disease may worsen outcomes from coronavirus disease 2019 (COVID-19) pneumonia in hospitalized patients: a systematic review, meta-analysis, and meta-regression. Parkinsonism Relat Disord 2021; 87: 155–61.CrossRef Google Scholar PubMed

Rajati, F, Ahmadi, N, Naghibzadeh, ZA, Kazeminia, M. The global prevalence of oropharyngeal dysphagia in different populations: a systematic review and meta-analysis. J Transl Med 2022; 20: 175.CrossRef Google Scholar PubMed

Banda, KJ, Chu, H, Chen, R, Kang, XL, Jen, HJ, Liu, D, et al. Prevalence of oropharyngeal dysphagia and risk of pneumonia, malnutrition, and mortality in adults aged 60 years and older: a meta-analysis. Gerontology 2022; 68: 841–53.CrossRef Google Scholar PubMed

Torres, A, Peetermans, WE, Viegi, G, Blasi, F. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax 2013; 68: 1057–65.CrossRef Google Scholar PubMed

Mitchell, SL, Teno, JM, Kiely, DK, Shaffer, ML, Jones, RN, Prigerson, HG, et al. The clinical course of advanced dementia. N Engl J Med 2009; 361: 1529–38.CrossRef Google Scholar PubMed

Antommaria, AHM, Gibb, TS, McGuire, AL, Wolpe, PR, Wynia, MK, Applewhite, MK, et al. Ventilator triage policies during the COVID-19 pandemic at U.S. hospitals associated with members of the association of bioethics program directors. Ann Intern Med 2020; 173: 188–94.CrossRef Google Scholar PubMed

Bledsoe, TA, Jokela, JA, Deep, NN, Snyder Sulmasy, L. Universal do-not-resuscitate orders, social worth, and life-years: opposing discriminatory approaches to the allocation of resources during the COVID-19 pandemic and other health system catastrophes. Ann Intern Med 2020; 173: 230–2.CrossRef Google Scholar

National Institute for Health and Care Excellence. COVID-19 rapid guideline: Critical care in adults (NICE Guideline NG159). NICE, 2022.Google Scholar

Centers for Disease Control and Prevention. About Underlying Cause of Death, 1999–2019. CDC WONDER, 2020 (https://wonder.cdc.gov/ucd-icd10.html).Google Scholar

Bartolomé, F, Rosa, L, Valenti, P, Lopera, F, Hernández-Gallego, J, Cantero, JL, et al. Lactoferrin as immune-enhancement strategy for SARS-CoV-2 infection in Alzheimer's disease patients. Front Immunol 2022; 13: 878201.CrossRef Google Scholar PubMed

Huang, LT, Zhang, CP, Wang, YB, Wang, JH. Association of peripheral blood cell profile with Alzheimer's disease: a meta-analysis. Front Aging Neurosci 2022; 14: 888946.CrossRef Google Scholar PubMed

De Zuani, M, Lazničková, P, Tomašková, V, Dvončová, M, Forte, G, Stokin, GB, et al. High CD4-to-CD8 ratio identifies an at-risk population susceptible to lethal COVID-19. Scand J Immunol 2022; 95: e13125.CrossRef Google Scholar PubMed

Numbers, K, Brodaty, H. The effects of the COVID-19 pandemic on people with dementia. Nat Rev Neurol 2021; 17: 69–70.CrossRef Google Scholar PubMed

Cheung, MW. A guide to conducting a meta-analysis with non-independent effect sizes. Neuropsychol Rev 2019; 29: 387–96.CrossRef Google Scholar PubMed

von Hippel, PT. The heterogeneity statistic I² can be biased in small meta-analyses. BMC Med Res Methodol 2015; 15: 35.CrossRef Google Scholar PubMed

Higgins, JPT, Thomas, J. Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons, 2019.CrossRef Google Scholar

Fig. 1 Flowchart on identification, screening and inclusion of eligible publications. ICU, intensive care unit.

Table 1. Characteristics of the studies included and samples reporting on SARS-CoV-2 infection risk.

Table 2. Characteristics of the studies included and samples reporting on COVID-19 course and outcome.

Table 3 Neurodegenerative disorders and SARS-CoV-2 infection risk from multivariable analyses

Table 4 Neurodegenerative disorders and COVID-19 severity, hospital admission, intenrtsive care unit admission and mortality from multivariable analyses

Fig. 2 Forest plot of pooled effect estimates for SARS-CoV-2 infection risk across all disorders.

Fig. 3 Forest plot of pooled effect estimates for COVID-19 mortality in people with dementia.

Smadi et al. supplementary material

Smadi et al. supplementary material 1

File 1.3 MB

Smadi et al. supplementary material

Smadi et al. supplementary material 2

Image 810.1 KB

This journal is not currently accepting new eletters.

eLetters

No eLetters have been published for this article.

Article contents

SARS-CoV-2 susceptibility and COVID-19 illness course and outcome in people with pre-existing neurodegenerative disorders: systematic review with frequentist and Bayesian meta-analyses

Abstract

Keywords

Information

Method

Search and selection strategy

Eligibility criteria

Exposure and outcome variables

Data extraction

Measures of effect

Assessment of methodological quality

Statistical analysis

Results

SARS-CoV-2 infection risk

COVID-19 course and outcome

Bayesian meta-analysis

Discussion

Susceptibility for SARS-CoV-2 infection and neurodegenerative disorders

Severity, course and outcome of SARs-CoV-2 and neurodegenerative disorders

Strength and limitations

Implications

Supplementary material

Data availability

Acknowledgements

Author contributions

Funding

Declaration of interest

References

Smadi et al. supplementary material

Smadi et al. supplementary material

eLetters

Save article to Kindle

Save article to Dropbox

Save article to Google Drive

Reply to: Submit a response

Your details

You have entered the maximum number of contributors

Conflicting interests